Online inquiry

IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7237MR)

This product GTTS-WQ7237MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets STAB1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_015136.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23166
UniProt ID Q9NY15
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7237MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7307MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ514MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ3333MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ13475MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ4633MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ8723MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ1712MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ15985MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW